Icatibant Viatris (Icatibant)

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. This inhibition stops the cascade that leads to the swelling characteristic of hereditary angioedema attacks.

The prescribed dose of Icatibant Viatris is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. Dosing instructions are individualized and should be followed exactly as written on the prescription.

Safety data for Icatibant Viatris in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace the deficient protein. Icatibant offers a subcutaneous route and rapid onset, making it useful for patients who prefer self‑administration and need quick symptom control.

Icatibant Viatris should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

The medication is supplied as a sterile injection solution for subcutaneous injection. A healthcare professional or the patient (after proper training) injects the dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique.

Serious risks include anaphylactic reactions, severe hypotension, and laryngeal edema that can compromise breathing. Patients should be monitored after injection, and any signs of severe allergic response or airway obstruction require immediate medical attention.

Icatibant Viatris is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Patients with a history of severe allergic reactions to bradykinin B2 antagonists should avoid this medication.